JPH0525470B2 - - Google Patents

Info

Publication number
JPH0525470B2
JPH0525470B2 JP56172908A JP17290881A JPH0525470B2 JP H0525470 B2 JPH0525470 B2 JP H0525470B2 JP 56172908 A JP56172908 A JP 56172908A JP 17290881 A JP17290881 A JP 17290881A JP H0525470 B2 JPH0525470 B2 JP H0525470B2
Authority
JP
Japan
Prior art keywords
urokinase
group
polyethylene glycol
molecular weight
triazine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP56172908A
Other languages
English (en)
Japanese (ja)
Other versions
JPS5896026A (ja
Inventor
Kimihiro Shimizu
Tsuguji Nakahara
Taketoshi Kinoshita
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nippon Chemiphar Co Ltd
Original Assignee
Nippon Chemiphar Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Chemiphar Co Ltd filed Critical Nippon Chemiphar Co Ltd
Priority to JP56172908A priority Critical patent/JPS5896026A/ja
Priority to ES516680A priority patent/ES8406542A1/es
Priority to US06/437,009 priority patent/US4495285A/en
Priority to BR8206347A priority patent/BR8206347A/pt
Priority to CH6304/82A priority patent/CH658669A5/fr
Priority to SE8206173A priority patent/SE457800B/sv
Priority to FR8218223A priority patent/FR2515684B1/fr
Priority to IT68274/82A priority patent/IT1191221B/it
Priority to GB08230987A priority patent/GB2110219B/en
Priority to DE19823240174 priority patent/DE3240174A1/de
Priority to CA000414556A priority patent/CA1203764A/en
Publication of JPS5896026A publication Critical patent/JPS5896026A/ja
Priority to US06/546,590 priority patent/US4640835A/en
Priority to CA000443230A priority patent/CA1217718A/en
Priority claimed from CA000443230A external-priority patent/CA1217718A/en
Publication of JPH0525470B2 publication Critical patent/JPH0525470B2/ja
Granted legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21073—Serine endopeptidases (3.4.21) u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6456—Plasminogen activators
    • C12N9/6462—Plasminogen activators u-Plasminogen activator (3.4.21.73), i.e. urokinase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP56172908A 1981-10-30 1981-10-30 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤 Granted JPS5896026A (ja)

Priority Applications (13)

Application Number Priority Date Filing Date Title
JP56172908A JPS5896026A (ja) 1981-10-30 1981-10-30 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
ES516680A ES8406542A1 (es) 1981-10-30 1982-10-20 Nuevos derivados de activadores plasminogenos
US06/437,009 US4495285A (en) 1981-10-30 1982-10-27 Plasminogen activator derivatives
BR8206347A BR8206347A (pt) 1981-10-30 1982-10-27 Processo para produzir derivados ativadores de plasminogenio
CH6304/82A CH658669A5 (fr) 1981-10-30 1982-10-28 Derives d'activateurs du plasminogene.
IT68274/82A IT1191221B (it) 1981-10-30 1982-10-29 Derivati di attivatori di plasminogeno procedimento per la loro preparazione ed agente trombolitico comprendente tali derivati
FR8218223A FR2515684B1 (fr) 1981-10-30 1982-10-29 Nouveau derive d'un activateur de plasminogene non immunogene d'origine humaine
SE8206173A SE457800B (sv) 1981-10-30 1982-10-29 Plasminogenaktivatorderivat
GB08230987A GB2110219B (en) 1981-10-30 1982-10-29 Plasminogen activator derivatives
DE19823240174 DE3240174A1 (de) 1981-10-30 1982-10-29 Neue plasminogen-aktivatorderivate
CA000414556A CA1203764A (en) 1981-10-30 1982-10-29 Plasminogen activator derivatives
US06/546,590 US4640835A (en) 1981-10-30 1983-10-28 Plasminogen activator derivatives
CA000443230A CA1217718A (en) 1981-10-30 1983-12-14 Plasminogen activator derivatives

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP56172908A JPS5896026A (ja) 1981-10-30 1981-10-30 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
CA000443230A CA1217718A (en) 1981-10-30 1983-12-14 Plasminogen activator derivatives

Publications (2)

Publication Number Publication Date
JPS5896026A JPS5896026A (ja) 1983-06-07
JPH0525470B2 true JPH0525470B2 (enExample) 1993-04-13

Family

ID=25670236

Family Applications (1)

Application Number Title Priority Date Filing Date
JP56172908A Granted JPS5896026A (ja) 1981-10-30 1981-10-30 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤

Country Status (9)

Country Link
US (1) US4495285A (enExample)
JP (1) JPS5896026A (enExample)
BR (1) BR8206347A (enExample)
CA (1) CA1203764A (enExample)
CH (1) CH658669A5 (enExample)
DE (1) DE3240174A1 (enExample)
FR (1) FR2515684B1 (enExample)
GB (1) GB2110219B (enExample)
SE (1) SE457800B (enExample)

Families Citing this family (197)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0098110B1 (en) * 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
JPS59196824A (ja) * 1983-04-21 1984-11-08 Kowa Co 吸着防止剤
JPS60176586A (ja) * 1984-02-21 1985-09-10 Sanwa Kagaku Kenkyusho:Kk 新規な修飾ウロキナ−ゼ、その製法並びにこれを含有する血栓溶解剤
GB8430252D0 (en) * 1984-11-30 1985-01-09 Beecham Group Plc Compounds
US4732863A (en) * 1984-12-31 1988-03-22 University Of New Mexico PEG-modified antibody with reduced affinity for cell surface Fc receptors
JPS61176532A (ja) * 1985-01-30 1986-08-08 Green Cross Corp:The プラスミノ−ゲンアクチベ−タ−前駆体の安定化方法
US4766106A (en) * 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4844897A (en) * 1985-09-13 1989-07-04 Hiroshi Maeda Anti-tumor protease preparations
JP2514950B2 (ja) * 1986-03-10 1996-07-10 エフ・ホフマン―ラ ロシユ アーゲー 化学修飾蛋白質，その製造法および中間体
US4791192A (en) * 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
CA1308377C (en) * 1987-08-21 1992-10-06 Henry Berger, Jr. Complex of polyethyleneglycol and tissue plasminogen activator
US5565519A (en) * 1988-11-21 1996-10-15 Collagen Corporation Clear, chemically modified collagen-synthetic polymer conjugates for ophthalmic applications
US5162430A (en) * 1988-11-21 1992-11-10 Collagen Corporation Collagen-polymer conjugates
US5510418A (en) * 1988-11-21 1996-04-23 Collagen Corporation Glycosaminoglycan-synthetic polymer conjugates
US5306500A (en) * 1988-11-21 1994-04-26 Collagen Corporation Method of augmenting tissue with collagen-polymer conjugates
US5166322A (en) * 1989-04-21 1992-11-24 Genetics Institute Cysteine added variants of interleukin-3 and chemical modifications thereof
US5843693A (en) * 1989-08-16 1998-12-01 Chiron Corporation Assay method for screening for inhibitors of proTNF conversion
US5998378A (en) * 1989-08-16 1999-12-07 Chiron Corporation Compositions for the inhibition of TNF hormone formation and uses thereof
US6586222B1 (en) 1989-08-16 2003-07-01 Chiron Corporation Recombinant PR-3 and compositions thereof
IT1260468B (it) * 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
US6063764A (en) * 1992-06-01 2000-05-16 Washington University & Chiron Corp. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
US20030171292A1 (en) * 1992-06-01 2003-09-11 Creasey Abla A. Method for using lipoprotein associated coagulation inhibitor to treat sepsis
WO1994001483A1 (en) * 1992-07-02 1994-01-20 Collagen Corporation Biocompatible polymer conjugates
JPH09505721A (ja) * 1992-10-20 1997-06-10 シータス オンコロジー コーポレイション インターロイキン６レセプターアンタゴニスト
AU709054B2 (en) 1994-03-07 1999-08-19 Chiron Corporation Compositions for the inhibition of TNF formation and uses thereof
US6833408B2 (en) * 1995-12-18 2004-12-21 Cohesion Technologies, Inc. Methods for tissue repair using adhesive materials
US7883693B2 (en) * 1995-12-18 2011-02-08 Angiodevice International Gmbh Compositions and systems for forming crosslinked biomaterials and methods of preparation of use
US6458889B1 (en) 1995-12-18 2002-10-01 Cohesion Technologies, Inc. Compositions and systems for forming crosslinked biomaterials and associated methods of preparation and use
DK1704878T3 (da) * 1995-12-18 2013-07-01 Angiodevice Internat Gmbh Tværbundne polymerpræparater og fremgangsmåder til deres anvendelse
WO1998003670A1 (en) * 1996-07-23 1998-01-29 Tanox Pharma B.V. Induction of t cell tolerance using a soluble molecule that can simultaneously block two costimulatory pathways
WO2000029431A1 (en) * 1998-11-17 2000-05-25 Tanox, Inc. Bispecific molecules cross-linking itim and itam for therapy
US7118743B2 (en) 1998-11-17 2006-10-10 Tanox, Inc. Bispecific molecules cross-linking ITIM and ITAM for therapy
WO2002030985A2 (en) 2000-10-10 2002-04-18 Tanox, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
JP2004514701A (ja) * 2000-11-30 2004-05-20 ネクター　セラピューティクス　エーエル，コーポレイション トリアジン誘導体の水溶性ポリマー複合体
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
EP1878441B1 (en) 2001-08-17 2018-01-24 Genentech, Inc. Complement pathway inhibitors binding to C5 and C5a without preventing the formation of C5b
US7320789B2 (en) 2001-09-26 2008-01-22 Wyeth Antibody inhibitors of GDF-8 and uses thereof
PL372138A1 (en) * 2001-10-15 2005-07-11 Chiron Corporation Treatment of sepsis by low dose administration of tissue factor pathway inhibitor (tfpi)
PL374966A1 (en) 2002-02-21 2005-11-14 Wyeth Follistatin domain containing proteins
AU2003303513A1 (en) * 2002-12-30 2004-07-29 Angiotech International Ag Tissue reactive compounds and compositions and uses thereof
US20040225077A1 (en) 2002-12-30 2004-11-11 Angiotech International Ag Drug delivery from rapid gelling polymer composition
EP2184298A1 (en) * 2003-03-14 2010-05-12 Wyeth a Corporation of the State of Delaware Antibodies against human IL-21 receptor and uses therefor
DK1682177T3 (da) 2003-11-04 2010-11-01 Novartis Vaccines & Diagnostic Anvendelse af antagonist-anti-CD40-antistoffer til behandling af kronisk lymfocytisk leukæmi
PT1682178E (pt) 2003-11-04 2010-10-21 Novartis Vaccines & Diagnostic Métodos de terapêutica para cancros que expressam o antigénio cd40
PT1684869E (pt) 2003-11-04 2011-09-16 Novartis Vaccines & Diagnostic Métodos de terapêutica para cancros relacionados com células b
EP1684805B8 (en) 2003-11-04 2010-08-25 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
DE602004028643D1 (de) 2003-11-04 2010-09-23 Novartis Vaccines & Diagnostic Verfahren zur behandlung von soliden tumoren mit expression des cd40-zelloberflächen-antigens
CN101189264B (zh) 2004-01-07 2017-10-10 诺华疫苗和诊断公司 M‑csf特异性单克隆抗体及其应用
US20050169970A1 (en) * 2004-02-02 2005-08-04 Unilever Bestfoods, North America Food composition with fibers
BRPI0508992A (pt) * 2004-03-17 2007-09-04 Chiron Corp tratamento de pneumonia severa pela administração de tfpi
BRPI0510477B1 (pt) 2004-04-28 2023-01-17 Angiotech Biomaterials Corporation Método para formar um gel e dispositivo para uso em aplicações médicas
CA2581093C (en) 2004-09-17 2014-11-18 Angiotech Biomaterials Corporation Multifunctional compounds for forming crosslinked biomaterials and methods of preparation and use
EP2842571A1 (en) 2004-11-30 2015-03-04 Celldex Therapeutics, Inc. Antibodies directed to GPNMB and uses thereof
AU2006208226A1 (en) * 2005-01-24 2006-08-03 Amgen Inc. Humanized anti-amyloid antibody
CN119119271A (zh) 2005-03-23 2024-12-13 根马布股份公司 用于治疗多发性骨髓瘤的cd38抗体
US20060269556A1 (en) * 2005-04-18 2006-11-30 Karl Nocka Mast cell activation using siglec 6 antibodies
NZ589687A (en) * 2005-07-21 2012-09-28 Genmab As Potency assays for antibody drug substance binding to an FC receptor
EP1913028B1 (en) * 2005-07-28 2015-03-04 Novartis AG Use of antibody to m-csf
JP5457671B2 (ja) * 2005-07-28 2014-04-02 ノバルティス アーゲー Ｍ−ｃｓｆ特異的モノクローナル抗体およびその使用
WO2007068255A1 (en) 2005-12-15 2007-06-21 Genmab A/S Use of effector-function-deficient antibodies for treatment of auto-immune diseases
TWI417301B (zh) 2006-02-21 2013-12-01 Wyeth Corp 對抗人類介白素-２２（ｉｌ-２２）之抗體及其用途
TW200744634A (en) 2006-02-21 2007-12-16 Wyeth Corp Methods of using antibodies against human IL-22
EP2010569A4 (en) 2006-03-20 2009-09-09 Xoma Technology Ltd HUMAN ANTIBODIES SPECIFIC TO GASTRINE MATERIALS AND METHODS
US20100196377A1 (en) 2006-04-13 2010-08-05 Jantapour Mary J Methods of treating, diagnosing or detecting cancer
TWI395754B (zh) 2006-04-24 2013-05-11 Amgen Inc 人類化之ｃ-ｋｉｔ抗體
CA2655623C (en) 2006-06-30 2017-12-12 Petrus Johannes Louis Spee Anti-nkg2a antibodies and uses thereof
KR20140033236A (ko) 2006-08-04 2014-03-17 노바르티스 아게 Ｅｐｈｂ3-특이적 항체 및 이의 용도
EA201201533A1 (ru) 2006-08-18 2014-11-28 Новартис Аг Prlr-специфическое антитело и его применения
MX2009006034A (es) 2006-12-07 2009-10-12 Novartis Ag Anticuerpos antagonistas contra ephb3.
GB0700133D0 (en) 2007-01-04 2007-02-14 Humabs Llc Human cytomegalovirus neutralising antibodies and use thereof
MX2009008104A (es) * 2007-02-02 2009-08-07 Amgen Inc Hepcidina, antagonistas de hepcidina y metodos de uso.
JP2010521180A (ja) 2007-03-14 2010-06-24 ノバルティス アーゲー 癌を処置、診断または検出するためのａｐｃｄｄ１阻害剤
CA3102679A1 (en) 2007-12-14 2009-06-25 Birgitte Urso Antibodies against human nkg2d and uses thereof
EP2261254A3 (en) 2007-12-21 2011-04-13 Amgen, Inc Anti-amyloid antibodies and uses thereof
AU2009207644A1 (en) 2008-01-24 2009-07-30 Novo Nordisk A/S Humanized anti-human NKG2A monoclonal antibody
US9175078B2 (en) 2008-01-25 2015-11-03 Amgen Inc. Ferroportin antibodies and methods of use
JP2011519279A (ja) 2008-05-01 2011-07-07 アムジエン・インコーポレーテツド 抗ヘプシジン抗体及び使用の方法
JP2011524858A (ja) 2008-05-15 2011-09-08 セレクシーズ ファーマスーティカルズ コーポレーション 抗ｐｓｇｌ−１抗体並びにその同定及び使用方法
PT2303923E (pt) 2008-07-16 2015-08-25 Inst Research In Biomedicine Anticorpos neutralizantes de citomegalovírus humano e sua utilização
NZ603499A (en) 2008-07-16 2014-05-30 Inst Research In Biomedicine Human cytomegalovirus neutralizing antibodies and uses thereof
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
US8685402B2 (en) * 2008-07-25 2014-04-01 Institute For Research In Biomedicine Neutralizing anti-influenza A virus antibodies and uses thereof
AU2009290091A1 (en) * 2008-09-08 2010-03-11 Ottawa Hospital Research Institute Periostin-induced pancreatic regeneration
CA2739551C (en) 2008-10-13 2019-03-05 Institute For Research In Biomedicine Dengue virus neutralizing antibodies and uses thereof
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
EP2432488A4 (en) 2009-03-20 2014-01-08 Amgen Inc SELECTIVE AND POWERFUL KV1.3 PEPTIDE INHIBITORS
US9885711B2 (en) 2009-09-25 2018-02-06 Xoma Technology Ltd. Screening methods
US8926976B2 (en) 2009-09-25 2015-01-06 Xoma Technology Ltd. Modulators
MX2012005864A (es) 2009-11-20 2012-08-31 Amgen Inc Proteinas de enlace al antígeno anti-orai 1 y usos de las mismas.
US20110212106A1 (en) 2010-01-20 2011-09-01 Institute For Research In Bioscience Hiv-1 neutralizing antibodies and uses thereof
EP3904391B1 (en) 2010-03-10 2024-07-10 Genmab A/S Monoclonal antibodies against c-met
CA2800785C (en) 2010-05-27 2019-09-24 Genmab A/S Monoclonal antibodies against her2
CA2800769C (en) 2010-05-27 2021-11-02 Genmab A/S Monoclonal antibodies against her2 epitope
SI2580243T1 (sl) 2010-06-09 2020-02-28 Genmab A/S Protitelesa proti humanemu CD38
PT2582728T (pt) 2010-06-15 2017-11-23 Genmab As Conjugados fármaco-anticorpo humano contra fator tecidual
EP2619226B1 (en) 2010-09-22 2018-09-12 Amgen Inc. Carrier immunoglobulins and uses thereof
AR083847A1 (es) 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US9550811B2 (en) 2010-12-02 2017-01-24 Bionor Immuno As Peptide scaffold design
PL2654781T3 (pl) 2010-12-21 2018-09-28 Novartis Ag Przeciwciała anty-p-selektynowe i sposoby ich zastosowania i identyfikacji
CN103347892B (zh) 2011-01-06 2016-11-02 比奥诺尔免疫有限公司 单体和多聚体免疫原性肽
US9499610B2 (en) 2011-04-08 2016-11-22 H. Lundbeck A/S Antibodies specific to pyroglutamated Aβ
WO2012143523A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
EP4520771A3 (en) 2011-04-20 2025-07-16 Genmab A/S Bispecifc antibodies against her2
KR102148982B1 (ko) 2011-06-03 2020-08-27 조마 테크놀로지 리미티드 Tgf-베타에 특이적인 항체
UA117901C2 (uk) 2011-07-06 2018-10-25 Ґенмаб Б.В. Спосіб посилення ефекторної функції вихідного поліпептиду, його варіанти та їх застосування
CA2841551C (en) 2011-07-18 2020-07-28 Institute For Research In Biomedicine Neutralizing anti-influenza a virus antibodies and uses thereof
ES2657470T3 (es) 2012-03-20 2018-03-05 Humabs Biomed S.A. Anticuerpos que neutralizan RSV, MPV y PVM y usos de los mismos
CA2874923C (en) 2012-06-06 2021-08-31 Bionor Immuno As Peptides derived from viral proteins for use as immunogens and dosage reactants
WO2014006217A1 (en) 2012-07-06 2014-01-09 Genmab B.V. Dimeric protein with triple mutations
EP3632462A1 (en) 2012-07-06 2020-04-08 Genmab B.V. Dimeric protein with triple mutations
UA105278C2 (ru) 2012-09-06 2014-04-25 Інститут Біології Клітини Нан України Способ получения каталитически активных антител (абзимов) с сиалидазной активностью
EP4434543A3 (en) 2013-01-10 2025-03-19 Genmab B.V. Human igg1 fc region variants and uses thereof
TWI682941B (zh) 2013-02-01 2020-01-21 美商再生元醫藥公司 含嵌合恆定區之抗體
HK1220466A1 (zh) 2013-03-14 2017-05-05 Regeneron Pharmaceuticals, Inc. 爱帕琳融合蛋白和其用途
CA2904357C (en) 2013-03-15 2020-09-22 Intrinsic Lifesciences Llc Anti-hepcidin antibodies and uses thereof
CN113667012B (zh) 2013-10-02 2024-07-12 免疫医疗有限责任公司 中和抗甲型流感抗体及其用途
BR112016016202A2 (pt) 2014-01-17 2017-09-19 Cedars Sinai Medical Center Construtos de direcionamento de receptores e uso dos mesmos
JP6913018B2 (ja) 2014-07-08 2021-08-04 ニューヨーク・ユニバーシティ タウイメージングリガンド、ならびにタウ異常症の診断および治療におけるそれらの使用
UA127198C2 (uk) 2014-07-11 2023-06-07 Ґенмаб А/С Антитіло, яке зв'язує axl
MX392761B (es) 2014-07-15 2025-03-21 Medimmune Llc Anticuerpos anti-influenza b neutralizantes y usos de los mismos.
US11786469B2 (en) 2014-07-22 2023-10-17 Cheolhee WON Silica nanoparticle composition for delivering bioactive material or protein such as a human proteasome
RU2021106673A (ru) 2014-07-24 2021-11-25 Дженентек, Инк. Способы конъюгации агента с тиольным компонентом в белке, который содержит по меньшей мере одну трисульфидную связь
NZ730186A (en) 2014-09-22 2020-04-24 Intrinsic Lifesciences Llc Humanized anti-hepcidin antibodies and uses thereof
US20170296650A1 (en) 2014-10-08 2017-10-19 Novartis Ag Combination of human cytomegalovirus neutralizing antibodies
WO2016062722A1 (en) 2014-10-24 2016-04-28 Astrazeneca Ab Combination
EP3215186A4 (en) 2014-11-04 2018-10-24 University of Southern California COMPOSITIONS AND METHODS FOR TREATING HIF-1alpha OVER-EXPRESSING CANCERS
WO2016075546A2 (en) 2014-11-14 2016-05-19 Antonio Lanzavecchia Antibodies that neutralize ebola virus and uses thereof
SI3220947T1 (sl) 2014-11-18 2021-02-26 Humabs Biomed S.A. Protitelesa, ki močno nevtralizirajo virus stekline in druge lisaviruse in njihove uporabe
CA3175979A1 (en) 2014-12-22 2016-06-30 Pd-1 Acquisition Group, Llc Anti-pd-1 antibodies
CA2981312C (en) 2015-03-30 2023-09-26 Regeneron Pharmaceuticals, Inc. Heavy chain constant regions with reduced binding to fc gamma receptors
US10441644B2 (en) 2015-05-05 2019-10-15 The Regents Of The University Of California H3.3 CTL peptides and uses thereof
ES2842849T3 (es) 2015-05-05 2021-07-15 Univ California Péptidos CTL H3.3 y usos de los mismos
US20160347848A1 (en) 2015-05-28 2016-12-01 Medimmune Limited Therapeutic combinations and methods for treating neoplasia
US10442854B2 (en) 2015-06-01 2019-10-15 Medimmune, Llc Neutralizing anti-influenza binding molecules and uses thereof
US20180179274A1 (en) 2015-06-26 2018-06-28 Institute For Research In Biomedicine Proteins comprising a mutated lair-1 fragment and uses thereof
EP3319993B1 (en) 2015-07-10 2020-01-15 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
GB201512215D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
GB201512203D0 (en) 2015-07-13 2015-08-19 Lundbeck & Co As H Agents,uses and methods
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US10988528B2 (en) 2015-08-13 2021-04-27 New York University Antibody-based molecules specific for the truncated ASP421 epitope of Tau and their uses in the diagnosis and treatment of tauopathy
ES2954969T3 (es) 2015-08-13 2023-11-27 Univ New York Moléculas basadas en anticuerpos selectivas para el epítopo {p}Ser404 de Tau y sus usos en el diagnóstico y tratamiento de la tauopatía
WO2017059878A1 (en) 2015-10-07 2017-04-13 Humabs Biomed Sa Antibodies that potently neutralize hepatitis b virus and uses thereof
EP3359575B1 (en) 2015-10-09 2020-07-22 Florida State University Research Foundation, Inc. Antibodies specific for 4,6-diamino-5-(formylamino) pyrimidine and uses thereof
AR108824A1 (es) 2015-11-21 2018-10-03 Fundacio Privada Inst De Recerca De La Sida Caixa Irsicaixa Derivados de anticuerpos contra el vih con actividad dual antiviral e inmunomodulatoria
KR20180101436A (ko) 2016-01-13 2018-09-12 메디뮨 엘엘씨 인플루엔자 a의 치료 방법
RS61646B1 (sr) 2016-07-12 2021-04-29 H Lundbeck As Antitela specifična za hiperfosforilisan tau i postupci njihove primene
WO2018010789A1 (en) 2016-07-13 2018-01-18 Humabs Biomed Sa Novel antibodies specifically binding to zika virus epitopes and uses thereof
EP3523330A1 (en) 2016-10-04 2019-08-14 Fairbanks Pharmaceuticals, Inc. Anti-fstl3 antibodies and uses thereof
WO2018083126A1 (en) 2016-11-01 2018-05-11 Genmab B.V. Polypeptide variants and uses thereof
AR110074A1 (es) 2016-11-15 2019-02-20 H Lundbeck As Agentes, usos y métodos para el tratamiento de la sinucleinopatía
DK3548058T3 (da) 2016-12-05 2022-09-26 Nuritas Ltd Sammensætninger omfattende peptid wkdeagkplvk
EP3329905A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Topical cosmetic compositions comprising an oligopeptide against anti-aging of the skin
EP3329930A1 (en) 2016-12-05 2018-06-06 Nuritas Limited Pharmaceuctical compositions
WO2018109058A1 (en) 2016-12-16 2018-06-21 H. Lundbeck A/S Agents, uses and methods
US10364286B2 (en) 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
MA47205A (fr) 2017-01-04 2019-11-13 H Lundbeck As Anticorps spécifiques de la protéine tau hyperphosphorylée pour traiter des maladies oculaires
JP6883354B2 (ja) 2017-02-06 2021-06-09 レモネックス インコーポレイテッドＬｅｍｏｎｅｘ Ｉｎｃ． 生理活性物質送達体
WO2018143787A1 (ko) 2017-02-06 2018-08-09 주식회사 레모넥스 생리활성물질 전달체
US12383609B2 (en) 2017-04-19 2025-08-12 Institute For Research In Biomedicine Plasmodium sporozoite NPDP peptides as vaccine and target novel malaria vaccines and antibodies binding to
CN111405910A (zh) 2017-05-10 2020-07-10 阿尔巴朱纳治疗有限公司 具有高HIV抗病毒和免疫调节双重活性的Fc融合蛋白衍生物
US10894833B2 (en) 2017-07-20 2021-01-19 H. Lundbeck A/S Agents, uses and methods for treatment
AU2018308088B2 (en) 2017-07-25 2025-05-29 Truebinding, Inc. Treating cancer by blocking the interaction of TIM-3 and its ligand
WO2019042555A1 (en) 2017-08-31 2019-03-07 Humabs Biomed Sa MULTISPECIFIC ANTIBODIES SPECIFICALLY BINDING TO ZIKA VIRUS EPITOPES AND USES THEREOF
KR102152348B1 (ko) 2017-09-05 2020-09-08 주식회사 레모넥스 세포 운명 조절용 조성물
WO2019145455A1 (en) 2018-01-24 2019-08-01 Genmab B.V. Polypeptide variants and uses thereof
MX2020008479A (es) 2018-02-14 2020-11-24 Viela Bio Inc Anticuerpos frente al ligando del receptor de tirosina cinasa 3 similar al sarcoma de mcdonough felino (fms) (flt3l) y tratamiento de enfermedades autoinmunes e inflamatorias.
EA202092593A1 (ru) 2018-04-30 2021-02-12 Такеда Фармасьютикал Компани Лимитед Белки, связывающие каннабиноидный рецептор 1-го типа (cb1), и их применение
US20210238229A1 (en) 2018-06-14 2021-08-05 University College Cork - National University Of Ireland, Cork Peptide for disease treatment
WO2020021061A1 (en) 2018-07-26 2020-01-30 Pieris Pharmaceuticals Gmbh Humanized anti-pd-1 antibodies and uses thereof
BR112021012094A2 (pt) 2018-12-19 2021-08-31 Humabs Biomed Sa Anticorpos isolados, proteína de fusão, polinucleotídeos isolados, vetor, célula hospedeira, composição farmacêutica, kit, método de produção, usos, métodos de tratamento, prevenção e/ou atenuação, de diagnóstico in vitro e para detectar a presença ou ausência de um epítopo
CN120058944A (zh) 2019-01-30 2025-05-30 真和制药有限公司 抗gal3抗体及其用途
CA3131700A1 (en) 2019-02-27 2020-09-03 Ionis Pharmaceuticals, Inc. Modulators of malat1 expression
JP7607579B2 (ja) 2019-03-27 2024-12-27 ティガティーエックス， インコーポレイテッド 工学的に操作されたＩｇＡ抗体および使用方法
KR20210150506A (ko) 2019-04-09 2021-12-10 압큐로, 인크. 킬러 세포 렉틴 유사-수용체 서브패밀리 G 구성원 1(KLRGl) 고갈 항체
EP3783012A1 (en) 2019-08-20 2021-02-24 Nuritas Limited An antimicrobial peptide
CN114650834A (zh) 2019-08-20 2022-06-21 努里塔斯有限公司 用于治疗肌肉萎缩的肽
EP4021578A1 (en) 2019-08-29 2022-07-06 VIR Biotechnology, Inc. Antibody compositions and methods for treating hepatitis b virus infection
CA3154368A1 (en) 2019-10-22 2021-04-29 Nora KHALDI Treatment of non-alcoholic fatty liver disease
EP3862014A1 (en) 2020-02-07 2021-08-11 Nuritas Limited Treatment of panx1 associated diseases
WO2021160887A1 (en) 2020-02-14 2021-08-19 Immunor As Corona virus vaccine
AU2021278935A1 (en) 2020-05-26 2022-12-08 Truebinding, Inc. Methods of treating inflammatory diseases by blocking Galectin-3
MX2022015765A (es) 2020-06-24 2023-03-27 Vir Biotechnology Inc Anticuerpos modificados neutralizadores del virus de la hepatitis b y sus usos.
WO2022148414A1 (zh) 2021-01-08 2022-07-14 北京韩美药品有限公司 特异性结合pd-l1的抗体及其抗原结合片段
EP4276113A4 (en) 2021-01-08 2025-04-09 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding to CD47 and antigen-binding fragment thereof
EP4276111A4 (en) 2021-01-08 2025-04-30 Beijing Hanmi Pharmaceutical Co., Ltd. Antibody specifically binding to 4-1bb and antigen-binding fragment of antibody
EP4284428A1 (en) 2021-01-26 2023-12-06 VIR Biotechnology, Inc. Compositions and methods for treating hepatitis b virus infection
WO2022204529A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
WO2022204514A1 (en) 2021-03-26 2022-09-29 Abcuro, Inc. Anti-klrg1 antibodies
WO2022212836A1 (en) 2021-04-01 2022-10-06 Pyxis Oncology, Inc. Gpnmb antibodies and methods of use
CN117642176A (zh) 2021-04-14 2024-03-01 爱尔兰国立科克大学 Psg1用于治疗骨关节炎
WO2022219008A1 (en) 2021-04-14 2022-10-20 University College Cork - National University Of Ireland, Cork Treatment of cerebrovascular events and neurological disorders
CA3227742A1 (en) 2021-07-26 2023-02-02 Abcuro, Inc. Killer cell lectin-like receptor subfamily g member 1 (klrg1) depleting antibodies
WO2023105281A1 (en) 2021-12-11 2023-06-15 Fundaciò Privada Institut De Recerca De La Sida-Caixa Soluble tigit recombinant proteins
CN117586388A (zh) 2022-08-09 2024-02-23 深圳智源生物医药有限公司 改进的β淀粉样蛋白寡聚体特异性结合抗体
CN117589996A (zh) 2022-08-09 2024-02-23 深圳智源生物医药有限公司 强毒性淀粉样蛋白寡聚体的诊断用途
WO2024078729A1 (en) 2022-10-14 2024-04-18 University College Cork - National University Of Ireland, Cork Placenta expressed proteins for use in the treatment of tendon injury
WO2025147544A1 (en) 2024-01-02 2025-07-10 Abcuro, Inc. Methods of treating inclusion body myositis (ibm)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2222080A1 (en) * 1973-03-22 1974-10-18 Viejo Jacques Stabilisation of pepsin - by salt formation with a carboxy polymethylene
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5623587A (en) * 1979-08-03 1981-03-05 Mitsuwa Seiki Co Ltd Vane type compressor
SU1022988A1 (ru) * 1979-09-28 1983-06-15 Всесоюзный кардиологический научный центр АМН СССР Стабилизированна урокиназа,обладающа тромболитической активностью,и способ ее получени

Also Published As

Publication number Publication date
DE3240174A1 (de) 1983-05-19
FR2515684A1 (fr) 1983-05-06
JPS5896026A (ja) 1983-06-07
GB2110219B (en) 1985-01-09
GB2110219A (en) 1983-06-15
FR2515684B1 (fr) 1986-04-04
DE3240174C2 (enExample) 1990-08-23
SE8206173L (sv) 1983-05-01
SE8206173D0 (sv) 1982-10-29
BR8206347A (pt) 1983-09-27
CA1203764A (en) 1986-04-29
SE457800B (sv) 1989-01-30
US4495285A (en) 1985-01-22
US4495285B1 (enExample) 1986-09-23
CH658669A5 (fr) 1986-11-28

Similar Documents

Publication Publication Date Title
JPH0525470B2 (enExample)
US4640835A (en) Plasminogen activator derivatives
US4552760A (en) Method for stabilizing tissue plasminogen activator and a stable aqueous solution or powder containing the same
JP2506521B2 (ja) Ｌｙｓ−プラスミノ―ゲンを含有する医薬
FI85334B (fi) Foerfarande foer framstaellning av en vattenbaserad, vaevnadsplasminogenaktivator (t-pa) innehaollande, koncentrerad parenterad loesning.
HU185223B (en) Process for preparing an enzymatic derivative containing a binary complex of streptokynase and plasminogen
JPH0357749B2 (enExample)
JPH01238536A (ja) 動脈の血栓症的閉塞または塞栓症を阻止するための医薬組成物
JPH07503454A (ja) プラズミンによる線維素溶解および線維素原溶解治療
JPH0231952B2 (enExample)
JP2690944B2 (ja) 組織プラスミノーゲンアクチベーター活性を有するタンパク質の高濃度溶液
JPS59172425A (ja) 新規な血液凝固因子誘導体およびその製造法ならびにそれを含有する血液凝固促進剤
JPH06183995A (ja) 組織プラスミノーゲン活性化因子含有医薬組成物
JP2978187B2 (ja) 修飾スーパーオキサイドディスムターゼの製造法
GB2221907A (en) Superoxide dismutase composition.
HU200277B (en) Process for producing pharmaceutical composition comprising human xiii factor as active ingredient
JPS6360938A (ja) 修飾組織型プラスミノ−ゲン活性化因子およびその製造方法
US20050143283A1 (en) Activated protein c formulations
JPH0195774A (ja) 修飾スーパーオキサイド・ジスムターゼ
JP2895626B2 (ja) 血栓溶解剤
EP0369035A1 (en) Agent for treating pancreatitis or the like
JPH0569508B2 (enExample)
JP2001518933A (ja) 血管障害の治療方法
JPH0215193B2 (enExample)
JPS59167520A (ja) 新規プラスミノ−ゲンアクチベ−タ誘導体およびその製造法ならびにそれを含有する医薬品